Primary cutaneous lymphomas and Coronavirus disease-2019: A critical overview of primary cutaneous lymphoma management in pandemic

Sinem Örnek, Aslı Bilgiç*, Serkan Yazıcı**, Dilek Bayramgürler***, Hatice Şanlı****, Nahide Onsun*****

University of Health Sciences Turkey, Dışkapı Yıldırım Beyazıt Training and Research Hospital, Clinic of Dermatology, Ankara, Turkey
*Akdeniz University Faculty of Medicine, Department of Dermatology, Antalya, Turkey
**Uludağ University Faculty of Medicine, Department of Dermatology, Bursa, Turkey
***Kocaeli University Faculty of Medicine, Department of Dermatology, Kocaeli, Turkey
****Ankara University Faculty of Medicine, Department of Dermatology, Ankara, Turkey
*****Bezmialem Vakıf University Faculty of Medicine, Department of Dermatology, İstanbul, Turkey

Abstract
Coronavirus disease-2019 (COVID-19) is a serious cause of respiratory tract infection, and its severe course has been associated with some risk factors, including malignancies and immunosuppressive treatments. Primary cutaneous lymphomas (PCL) are a heterogeneous group of immune system neoplasms, which are subclassified as indolent and aggressive types according to their survival rates. PCL treatment ranges from skin-based therapies to systemic treatments, of which immunosuppressive effects occur in some. During the COVID-19 pandemic, patients with PCL should be protected from possible COVID-19 complications, and the optimal treatment should be provided to control the disease taking into account the treatment-related risks. Therefore, recommendations about the management of patients with PCL during the COVID-19 pandemic were overviewed in light of the literature. Topical treatments can generally be considered low-risk therapies and can be continued without interruption. Phototherapy, skin radiotherapy, and total skin electron beam therapy increase the risk of COVID-19 exposure due to hospital visits. Moderate-risk therapies like interferons, systemic retinoids, methotrexate, and systemic corticosteroids might be used with caution. Advanced-stage patients with COVID-19 related comorbidity and who previously received immunosuppressive therapy should be carefully evaluated. Biological agents and systemic chemotherapeutics, which are considered high-risk, should not be delayed when needed. However, increasing intervals between treatments or switching to alternative therapies may be preferable in stable diseases. Most importantly, all patients with PCL should be ensured to comply with general protection measures as long as the pandemic continues.

Keywords: Primary cutaneous lymphoma, COVID-19, management

Öz
Koronavirüs hastalığı-2019 (COVID-19), solunum yolu enfeksiyonunun ciddi bir nedenidir ve kişisel ve immünsupresif tedavilerle de riskleri nedenide dikkate alınarak tedavi edilmişdir. Primer kutanöz lenfomalar (PKL), sağkalım oranına göre indolent ve agresif tipler olarak sınıflandırılan heterojen bir immün sistem neoplazmaları grubudur. PKL’erin tedavisi, deriye yönelik tedavilerden sistemik tedavilere kadar uzanır ve bununla birlikte en riskli tedavilerdir. COVID-19 salgını sırasında, PKL’li hastaların corona virüs salgınına karşı korunması, tedaviye bağlı riskler de dikkate alınarak hasta kontrol altına alındığında optimal tedavi sağlanmalıdır. Bu bağlamda, COVID-19 pandemi sırasında PKL yönetimine ilgili öneriler literatür ışığında gözden geçirildi. Topikal tedaviler genellikle düşük riskli tedaviler olarak bilinen tedavilerdeki riskler arz etmeli, tedavi sürelerinin uzatılması ve alternatif tedavi seçimi ise tedavi durumuna bağlı olarak tercih edilebilir. En önemlidisi, PCL hastalarına pandemi süresince genel koruyucu tedavilerinin uygulanması sağlanmalıdır.

Address for Correspondence/Yazıma Adresi: Sinem Örnek MD, University of Health Sciences Turkey, Dışkapı Yıldırım Beyazıt Training and Research Hospital, Clinic of Dermatology, Ankara, Turkey
Phone: +90 312 596 20 00 E-mail: drsineomnek@yahoo.com Received/Geliş Tarihi: 19.03.2021 Accepted/Kabul Tarihi: 03.12.2021

Cite this article as: Örnek S, Bilgiç A, Yazıcı S, Bayramgürler D, Şanlı H, Onsun N. Primary cutaneous lymphomas and Coronavirus disease-2019: A critical overview of primary cutaneous lymphoma management in pandemic. Turkderm-Turk Arch Dermatol Venereol 2022;56:1-6

©Copyright 2022 by Turkish Society of Dermatology and Venereology
Turkderm-Turkish Archives of Dermatology and Venereology published by Galenos Yaynevi.
Introduction

Coronavirus disease-2019 (COVID-19) is an infectious disease caused by severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2)\(^1\). It can be clinically asymptomatic or cause severe viral pneumonia, which can lead to respiratory failure and even death\(^1\). Some patient groups might be more susceptible to this infection due to their risk factors, including their disorders and relevant medications\(^2\). One of these vulnerable patient groups may be claimed as patients with primary cutaneous lymphoma (PCL). They seem to be at risk of developing complications during COVID-19 as they are usually older with comorbidities and are receiving immunosuppressive therapy to provide long-term disease control. Additionally, the uncontrolled disease of patients with PCL correlates to a higher incidence of infection as the disease itself may cause an immunosuppressive state. Thus, during the COVID-19 pandemic, patients with PCL should be protected from possible COVID-19 complications and optimal balance should be provided while managing the disease. Therefore, recommendations regarding the management of patients with PCL during the COVID-19 pandemic were overviewed in light of the literature.

Stratification of PCL according to their risks

PCL is a heterogeneous group of immune system neoplasms that are characterized by T-lymphocyte, B-lymphocyte, or natural killer (NK) cell proliferation and their orientation to the skin\(^1\). Of PCL, 73% are cutaneous T-cell lymphoma (PCTL), 22% are cutaneous B-cell lymphoma (PCBL), and the remainder is other rare cutaneous lymphomas, such as NK-cell neoplasms\(^2\). They are categorized into indolent and aggressive types based on the World Health Organization/European Organization for Research and Treatment of Cancer (EORTC) classification\(^3,4\). Additionally, the United States Cutaneous Lymphoma Consortium classified them into subgroups according to risk as low, intermediate-low, intermediate- high, and high\(^5\). The risk groups of PCL were gathered under a single table taking into account the risk of COVID-19 complications (Table 1)\(^6\).

The risk of COVID-19 infection of patients with low-risk, especially those that do not receive systemic therapy, is thought to bear the same risk as to the general population. However, patients with advanced disease are more susceptible to opportunistic infections and probably to a more severe COVID-19 infection since their immune systems are already defective even if they do not receive systemic therapy\(^5\). Mycosis fungoides (MF), which is the most common type of PCTL, have an indolent course in the majority of patients. Still, factors like older age, comorbidities, immunosuppressive therapies, advanced stage, and aggressive disease are important risk factors to consider in this patient group during the COVID-19 outbreak\(^6\).

Recommendations for PCL management during the COVID-19 pandemic

1. General protection measures

First of all, patients with PCL should be ensured to comply with general protection measures as long as the pandemic continues. The risk of viral transmission was shown to reduce when precautions are taken against contamination through droplets and contamination from surfaces\(^7\). Patients should be informed that COVID-19 spreads by droplets and the best way of protection are to wear a mask around others. They should be warned to wash their hands very frequently and dully, not to touch their face with hands, not to spend time in crowded environments, and not to approach anyone >2 m. They should also be

| Table 1. The risk groups of primary cutaneous lymphomas\(^1,3,7\) | Aggressive PCLs |
|---------------------------------------------------------------|-----------------|
| **Indolent PCLs**                                             | **Low risk**    | **Low-moderate risk** | **Moderate-high risk** | **High risk** |
| MF stage IA                                                 | MF stage IB     | MF stage IIIB (tumors) | MF stage IV            |
| MF stage IB (patches or limited BSA)                        | MF stage 2A     | MF stage III (erythrodemic) | Transformed MF         |
| Pagetoid reticulosis                                        | Folliculotrop MF | PC diffuse large B-cell lymphoma, not leg-type | Sézary syndrome |
| Lymphomatoid papulosis                                      | Granulomatous MF | -                      | PC CD8+ aggressive epidermotropic cytotoxic T-cell lymphoma |
| PC CD4+ small/medium T-cell lymphoproliferative disorder    | Granulomatous slack skin | -                      | PC gamma/delta T-cell lymphoma |
| PC Acral CD8+ T-cell lymphoma                                | PC anaplastic large cell lymphoma | -                      | Extranodal NK/T-cell lymphoma |
| PC marginal zone B-cell lymphoma                             | Subcutaneous panniculitis-like T-cell lymphoma | -                      | PC diffuse large B-cell lymphoma, leg-type |
| PC follicle center B-cell lymphoma                           | -               | -                      | -                      |

PCL: Primary cutaneous lymphoma, MF: Mycosis fungoides, BSA: Body surface area, LAP: Lymphadenopathy, PC: Primary cutaneous
informed about skincare and how to avoid traumas that could disrupt the integrity of the skin\(^8\).

2. Skin-directed therapies

Skin-directed therapies that are used in PCL were summarized in Table 2, and the risk categories regarding COVID-19 complications for each treatment option were noted. The majority of patients with MF present with limited disease and are preferentially treated with skin-directed therapies. Skin-directed therapies are generally considered low-risk therapies for COVID-19 complications. The United States Cutaneous Lymphoma Consortium and EORTC Cutaneous Lymphoma Task Force recommend topical therapies as initial treatment in patients with low-risk\(^7,8\), and low-risk therapies that can be used at home should be continued for all patients (Table 2).

Phototherapy is a low-risk therapy; however, the exact risk of the spread of SARS-CoV-2 through phototherapy units is still unknown. It may increase infection exposure due to hospital admission, thus experts subclassify phototherapy in the high-risk category\(^7\). Some countries temporarily closed phototherapy units during the peak of the pandemic to prevent in-hospital viral spread by outpatients or because some dermatological units were converted into COVID-19 treatment zones\(^10\). A study evaluated the disease status of patients who stopped receiving phototherapy and revealed that 95% of patients who stopped phototherapy for any reason reported a disease status worsening, and determining the number of patients who avoided SARS-CoV-2 infection because of this decision is difficult\(^9\).

Phototherapy is an important treatment option for cutaneous T-cell lymphomas, and the decision of performing psoralen and ultraviolet A or narrowband ultraviolet B treatments in hospitals should be made based on the hospital feasibility and COVID-the prevalence in that specific location, considering individual factors for each patient after a risk/benefit assessment\(^6\). In hospitals, where phototherapy units are available, a fewer number of patients than usual can be accepted with longer appointment intervals on the same day. While using phototherapy units during the pandemic, some special safety measures should be taken for the safety of patients and healthcare professionals\(^12,14\).

Before performing phototherapy, all patients should be evaluated for COVID-19-related symptoms, and in case of COVID-19 suspicion, the treatment of the suspected patient should be postponed. All patients should apply hand sanitizer upon entering and leaving the phototherapy unit and wear facial masks during the phototherapy, except for total body phototherapy treatment. Patients should be advised to bring a separate bag to put their clothes in before entering the phototherapy unit. Additionally, patients should be informed that at the end of each session they can disinfect their UV protective glasses following the manufacturer’s recommendations\(^12,14\). Without specific recommendations, the glasses can be disinfected using wipes that contain 70-90% ethyl alcohol\(^15\).

The cleaning staff who works in coordination with the infection committee should be specifically trained on how to professionally clean phototherapy units. The phototherapy units should be ventilated for at least 15 min after each patient, and the floor of the units and the surfaces that were touched by the patients should be disinfected following the manufacturer’s instructions\(^12,14\). Without specific recommendations, disinfectants containing quaternary ammonium (following the product label for use and dilution) can be used\(^15\). Bleach and alcohol should not be preferred as the former creates corrosion on surfaces and the latter causes toxicity when used on

### Table 2. Skin-directed therapies\(^7,9\)

| Skin-directed therapies | Mechanism of action |
|-------------------------|---------------------|
| **Low-risk**             |                     |
| Moisturizers            | Restore skin barrier and reduce microorganism colonization |
| Diluted vinegar or bleach soaks/baths | Reduce microorganism colonization |
| Topical corticosteroids | Induce apoptosis of lymphocytes and prevent binding of lymphocytes to the endothelium |
| Mechlorethamine gel/ointment\(^a\) | Alkylating chemotherapeutic agent |
| Topical imiquimod       | Induces Th1 cytokines and causes apoptosis of malignant cells |
| **Topical retinoids**    |                     |
| Bexarotene              | RXR receptor agonist. Induces apoptosis of malignant cells |
| Tazarotene              | RAR receptor agonist. Provides antiproliferative and anti-inflammatory activity |
| Home narrowband UVB phototherapy | Provides anti-proliferative and anti-inflammatory activity and causes apoptosis of T-cells |
| **Moderate-risk**       |                     |
| Topical carmustine\(^b\) | Alkylating chemotherapeutic agent |
|                         | Induces apoptosis by crosslinking to DNA and RNA |
| **High-risk**           |                     |
| Office-based phototherapy (nbUVB and PUVA)\(^c\) | Provides antiproliferative and anti-inflammatory activity and causes apoptosis of T-cells |
| Skin radiotherapy\(^d\) | Causes death of tumoral cells by damaging DNA |
| Total skin electron beam therapy\(^e\) | Causes death of tumoral cells by damaging DNA |

\(^a\): Not available in Turkey. \(^b\): Myelosuppressive effect may occur due to systemic absorption. Can be used if involvement is <3% of body surface area. Maintenance therapy is contraindicated. \(^c\): The risk increases due to the frequency of hospital visits and the risk of Coronavirus disease-2019 exposure. nbUVB: Narrowband ultraviolet B, PUVA: Psoralen and ultraviolet A.
large surfaces. The phototherapy units should be re-ventilated after disinfection.

Skin radiotherapy and total skin electron beam therapy also increase the risk of COVID-19 exposure due to frequent hospital visits, as in office-based phototherapy\(^7\). Cutaneous anaplastic large cell lymphoma and low-risk PCBLs are usually locally treated with surgical excision or radiotherapy. Thus, continuing or postponing these treatments should be individually evaluated\(^7\).

3. Systemic therapies

Systemic therapies that were used in PCL were summarized in Table 3, and categories in COVID-19 complications of each treatment option were noted.

Moderate and high-risk therapies are required for the management of advanced and aggressive forms of cutaneous lymphomas. The well-controlled disease is associated with fewer infections, but treatment-based risks may overshadow this good outcome, thus the issue of how to use these drugs during the COVID-19 pandemic arises. Firstly, all treatment decisions should be made considering the benefits and risks of treatments individually for each patient. The United States Cutaneous Lymphoma Consortium stated that the initiation of moderate-risk therapies can be delayed for a short time using low-risk therapies, and moderate-risk therapies can be continued in patients who are already using them; however, individual dose adjustments may be considered (Table 3)\(^6\). The benefits of moderate-risk systemic treatments, such as interferon alfa-2 or bexarotene, generally overcome the risks in case of potential COVID-19 infection, thus they can be continued during the COVID-19 outbreak. In patients who use high-risk therapies, retinoids or interferons can be preferred instead of high-risk therapy for the short-term as a bridge therapy, and increasing the doses of retinoids and/or interferons can be individually considered\(^7,8\).

Concerns arise that methotrexate may increase the risk of COVID-19 complications due to its immunosuppression effects although it is not proven. Thus, decreasing the dose or increasing the intervals between treatments may be considered. Additionally, dose reduction or switching to low-risk therapies should be considered in patients who use systemic corticosteroids since it takes a while for the immune system to return to normal levels after stopping systemic corticosteroids\(^7,8\).

High-risk therapies cannot be directly prescribed by dermatologists in Turkey, and they are usually applied by hematologists/oncologists. However, this study might contribute to the decision process of using high-risk therapies by sharing our opinions with our colleagues during consultation. High-risk therapies, in addition to their potential risks, like immunosuppression, may increase the COVID-19 exposure by requiring hospital travel. However, patients with active, advanced, and aggressive malignancies should be treated without delay since uncontrolled malignancies alone cause susceptibility to infections and worse outcomes\(^8\). Thus, high-risk therapies should be used only in high-risk patients, considering the additional travel risk\(^7\). The ongoing high-risk therapies of patients with advanced PCL should not be prophylactically stopped\(^8\). However, with stable or in partial remission diseases, increasing intervals between treatments or switching to alternative therapies may be preferable, especially in older patients with comorbidities\(^7,8\). Allogeneic stem cell transplant

| Table 3. Systemic therapies\(^6,9\) |
|-----------------------------------|
| **Systemic therapies** | **Mechanism of action** | **Risk** | **Notes** |
| **Moderate-risk** | | | |
| Interferons (alpha or gamma)\(^a\) | Activates antitumor cytolytic cells (NK and T-cell), inhibits the growth of malignant T-cells, and increases Th1 cytokine response | | |
| **Retinoids\(^b\)** | | | |
| Bexarotene | RXR receptor agonist | Regulates biological response and induces apoptosis of malignant cells | | |
| Acitretin | RAR receptor agonist | Shows anti-inflammatory and antiproliferative activities | | |
| Methotrexate | Stops cell division by inhibiting DNA synthesis, and shows anti-inflammatory and antiproliferative activities | | |
| Systemic corticosteroids | Reduces proinflammatory cytokines and inflammatory cell migration | | |
| Vorinostat\(^c\) | Histone deacetylase enzyme inhibitor. Induces apoptosis | | |
| **High-risk** | | | |
| Extracorporeal phototherapy\(^d\) | Causes apoptosis of circulating malignant lymphocytes and induces Th1 cytokines | | |
| Pralatrexate\(^e\) | Stops cell division by inhibiting DNA, RNA, and protein synthesis | | |
| Romidepsin\(^e\) | Histone deacetylase enzyme inhibitor. Induces apoptosis | | |
| Mogamulizumab\(^f\) | Anti-CCR4 antibody. Causes antibody-dependent cellular cytotoxicity leading to the death of malignant cells | | |
| Brentuximab vedotin\(^f\) | Anti-CD30 antibody. Induces apoptosis | | |
| Gemcitabine\(^e\) | Stops cell division by inhibiting DNA synthesis | | |
| Alemtuzumab\(^e\) | Anti-CD52 antibody. Causes antibody-dependent cellular cytotoxicity leading to the death of malignant cells | | |
| Other chemotherapies\(^f\) (CHOP or fludarabine) | Stops cell division by inhibiting DNA synthesis | | |
| Rituximab | Anti-CD20 antibody. Causes mature B-cell apoptosis | | |

\(^{a,b,c,d,e,f}\) Not available in Turkey for a while. \(^b\) Do not cause immunosuppression. \(^c\) Not available in Turkey. \(^d\) The risk increases due to the frequency of hospital visits and the risk of COVID-19 exposure. Do not cause generalized immunosuppression. \(^e\) Can be applied by hematologists/oncologists in Turkey. \(^f\) They are not recommended as they cause significant cytopenia. CHOP: Cyclophosphamide, hydroxyrubicin, vincristine, prednisone.
and cyclophosphamide, hydroxyuridine, vincristine, prednisone, alemtuzumab, and fludarabine treatment are not recommended since they lead to pronounced cytopenia, which is a well-known risk factor for COVID-19 complications. Alternative therapies with lower risks should be used instead.

No significant evidence was found for the increased risk of severe COVID-19 infection following rituximab; however, some case reports stated that rituximab outcomes on COVID-19 were severe in patients with systemic lymphoma/leukemia. Additionally, persisting viremia, COVID-19 virus reactivation, and prolonged COVID-19-associated pneumonia have been associated with rituximab and its resultant B-cell depletion. Rituximab treatment is not urgent for patients with indolent disseminated B-cell lymphoma. Thus, it can be delayed for up to 2 months. However, for patients with aggressive B-cell lymphoma, rituximab treatment should be continued during the pandemic.

4. Inpatient clinics
At the beginning of the pandemic and at the peak times, inpatient clinics were reorganized and most of the beds were reserved for patients with COVID-19. In most dermatology inpatient clinics, only a few beds are reserved for urgent dermatological cases. Therefore, the number of hospitalized patients was observed to dramatically decrease compared with the number of hospitalizations in the same period in previous years. Unfortunately, the delay in hospitalization and treatment of people with chronic diseases and malignancies played a role in the increased number of deaths during the pandemic period. Therefore, in all treatment decisions, patients in need for hospitalization should be individually evaluated and necessarily hospitalized by providing appropriate conditions. Before a hospitalization, patients should be questioned about their state of health and any contact with patients having COVID-19 and should be tested for COVID-19 to ensure their status. Additionally, patients should be encouraged to wear masks and keep them on throughout the whole visit.

5. Vaccination against COVID-19
Currently, cutaneous lymphoma-specific information regarding vaccinations was unavailable. Recommendations are based on experts’ opinions due to the limitations in prospective data in the vaccination of patients with active malignancy. The National Comprehensive Cancer Network COVID-19 Vaccination Advisory Committee strongly suggests that COVID-19 vaccines should be given to all patients with cancer, as well as household contacts (≥16 years of age) and caregivers when they are eligible to receive the vaccine. Further, the committee has no preference for any of the approved vaccines. Australia and New Zealand have achieved excellent community control of COVID-19 infection. The Hematology Society of Australia and New Zealand and infectious diseases specialists have collaborated on a consensus position statement regarding COVID-19 vaccination in patients with hematological disorders including lymphomas. The Centers for Disease Control and Prevention recommends for those 12 years and older get a COVID-19 vaccine, which includes people with underlying medical conditions such as cancer. Large cohort studies revealed that patients with cancer are at high-risk for COVID-19 and vaccine trials have revealed that vaccines decrease the incidence of COVID-19 disease and complications; however, data suggest that vaccines may prevent SARS-CoV-2 infection and subsequent transmission risk are limited. Therefore, even if vaccinated, patients and close contacts should continue to wear masks, maintain social distancing guidelines, and follow other recommendations for COVID-19 prevention.

The key principles are as follows:
1. Individuals with active cancer or those with active, recent (<6 months), or scheduled cancer treatment should be considered the highest priority to receive one of the currently available COVID-19 vaccines.
2. A history of cancer is unknown in increasing the risk for severe COVID-19. People with a history of cancer treatment may want to discuss their concerns about COVID-19 with their doctors.
3. Data on dual vaccination are unavailable, thus COVID-19 vaccines should be prioritized over other needed vaccines. A 14-day interval between COVID-19 vaccines and other approved vaccines is recommended.
4. For patients who have already started disease-specific therapies, therapy discontinuation at the time of vaccination is generally not recommended.
5. Some evidence pointed that patients undergoing cancer treatment or who are somehow immunocompromised may have a poorer vaccine response. Thus, delaying vaccination may be considered until immunosuppressive therapy is reduced and/or based on immunophenotyping of T-cell and B-cell immunity.
6. If possible, patients should be vaccinated 14 days before chemotherapy, cellular therapies, or T- or B-cell depleting therapies, but this should not delay urgent treatment.
7. Delaying vaccination for at least 3 months after B-cell-depleting therapy or stem cell transplantation is appropriate.
8. The efficacy of COVID-19 vaccines, particularly in patients with cutaneous lymphoma is unknown, thus vaccination in these patients should not replace other public health measures.

Conclusion
The majority of patients with PCL have an indolent course. Thus, low-risk therapies can be continued without interruption, and moderate-risk therapies might be used with caution. However, patients with advanced-stage COVID-19-related comorbidity and patients who previously received immunosuppressive therapy should be carefully evaluated. Most importantly, all patients with PCL should be ensured to comply with general protection measures as long as the pandemic continues. COVID-19 vaccines should be given to all patients with cancer, as eligible. These recommendations should be considered in the context of individual needs of patients, hospital resources, and COVID-19 outbreak prevalence in that specific location.

Ethics
Peer-review: Internally peer-reviewed.

Authorship Contributions
Surgical and Medical Practices: S.Ö., A.B., S.Y., D.B., H.Ş., N.O., Concept: S.Ö., A.B., S.Y., D.B., H.Ş., N.O., Design: S.Ö., A.B., S.Y., D.B., H.Ş., N.O., Data Collection or Processing: S.Ö., A.B., S.Y., D.B., H.Ş., N.O., Analysis or Interpretation: S.Ö., A.B., S.Y., D.B., H.Ş., N.O., Literature Search: S.Ö., A.B., S.Y., D.B., H.Ş., N.O., Writing: S.Ö., A.B., S.Y., D.B., H.Ş., N.O.

Conflict of Interest: No conflict of interest was declared by the authors.
Financial Disclosure: The author declared that this study received no financial support.

References
1. Huang C, Wang Y, Li X, et al.: Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020;395:497-506.
2. Lu R, Zhao X, Li J, et al.: Genomic characterisation and epidemiology of 2019 novel coronavirus: Implications for virus origins and receptor binding. Lancet 2020;395:565-74.
3. Jordan RE, Adab P, Cheng KK: COVID-19: Risk factors for severe disease and death. BMJ 2020;368:m1198.
4. Guan WJ, Ni ZY, Hu Y, et al.: Clinical characteristics of Coronavirus disease 2019 in China. N Engl J Med 2020;382:1708-20.
5. Willemeze R, Cerroni L, Kempf W, et al.: The 2018 update of the WHO-EORTC classification for primary cutaneous lymphomas. Blood 2019;133:1703-14.
6. Trautinger F, Eder J, Assaf C, et al.: European Organisation for Research and Treatment of Cancer consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome - Update 2017. Eur J Cancer 2017;77:57-74.
7. Zic JA, Ai W, Akilov OE, et al.: United States Cutaneous Lymphoma Consortium recommendations for treatment of cutaneous lymphomas during the COVID-19 pandemic. J Am Acad Dermatol 2020;83:703-4.
8. Papadav E, Scarsbrick J, Ortiz Romero P, et al.: Management of primary cutaneous lymphoma patients during COVID-19 pandemic: EORTC CLTF guidelines. J Eur Acad Dermatol Venereol 2020;34:1633-6.
9. Seto WH, Tsang D, Yung RW, et al.: Effectiveness of precautions against droplets and contact in prevention of nosocomial transmission of severe acute respiratory syndrome (SARS). Lancet 2003;361:1519-20.
10. Mateeva V, Patatsi A: Management of primary cutaneous lymphomas during the COVID-19 pandemic. Clin Dermatol 2021;39:64-75.
11. Costa FB, Baptista PL, Duquia RP: A cross-sectional questionnaire study in a phototherapy unit during COVID-19. Photocem Photobiol Sci 2021;20:1239-42.
12. Pacifico A, Ardigo M, Frascione P, Damiani G, Morrone A: Phototherapeutic approach to dermatology patients during the 2019 coronavirus pandemic: real-life data from the Italian red zone. Br J Dermatol 2020;183:375-6.
13. Aguilar P, Gilberte Y, Perez-Ferrillos A, et al.: Management of phototherapy units during the COVID-19 pandemic: Recommendations of the AEDV’s Spanish Photobiology Group. Actas Dermosifiliogr (Engl Ed) 2021;112:73-5.
14. Lim HW, Feldman SR, Van Voorhees AS, Gelfand JM: Recommendations for phototherapy during the COVID-19 pandemic. J Am Acad Dermatol 2020;83:287-8.
15. Guideline for disinfection and sterilization in healthcare facilities. [accessed by: 19 November 2011]. https://www.cdc.gov/infectioncontrol/guidelines/disinfection/tables/table1.html
16. Yang J, Zheng Y, Guo X, et al.: Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: A systematic review and meta-analysis. Int J Infect Dis 2020;94:91-5.
17. Wang T, Du Z, Zhu F, et al.: Comorbidities and multi-organ injuries in the treatment of COVID-19. Lancet 2020;395:e52.
18. Tepasse PR, Hafezi W, Lutz M, et al.: Persisting SARS-CoV-2 viraemia after rituximab therapy: two cases with fatal outcome and a review of the literature. Br J Haematol 2020;190:185-8.
19. Lancman G, Mascarenhas J, Bar-Natan M: Severe COVID-19 virus reactivation following treatment for B cell acute lymphoblastic leukemia. J Hematol Oncol 2020;13:131.
20. Kos I, Balenseifer B, Roth S, et al.: Prolonged Course of COVID-19-associated pneumonia in a B-cell depleted patient after rituximab. Front Oncol 2020;10:1578.
21. Wilcox RA: Cutaneous T-cell lymphoma: 2017 update on diagnosis, risk stratification, and management. Am J Hematol 2017;92:1085-102.
22. Patrizi A, Bardazzi F, Filippi F, Abbenante D, Piraccini BM: The COVID-19 outbreak in Italy: Preventive and protective measures adopted by the Dermatology Unit of Bologna University Hospital. Dermatol Ther 2020;33:e13469.
23. Bialynicki-Birula R, Siemasz I, Otlevska A, Matusiak L, Szeplietowski JC: Influence of COVID-19 pandemic on hospitalizations at the tertiary dermatology department in south-west Poland. Dermatol Ther 2020;33:e13738.
24. Mateeva V, Vassileva S: Impact of COVID-19 pandemic on the management of cutaneous lymphomas. Clin Dermatol 2021;39:169-71.
25. Hanna TR, King WD, Thibodeau S, et al.: Mortality due to cancer treatment delay: Systematic review and meta-analysis. BMJ 2020;371:m4087.
26. Recommendations of the National Comprehensive Cancer Network® (NCCN®) COVID-19. [accessed by 19 November 2011]. Vaccination Advisory Committee https://www.nccn.org/docs/default-source/covid-19/2021_(NCCN®) COVID-19. [accessed by 19 November 2011]. Vaccination Advisory Committee https://www.nccn.org/docs/default-source/covid-19/2021_(NCCN®) COVID-19. [accessed by 19 November 2011]. Vaccination Advisory Committee https://www.nccn.org/docs/default-source/covid-19/2021_(NCCN®) COVID-19. [accessed by 19 November 2011]. Vaccination Advisory Committee https://www.nccn.org/docs/default-source/covid-19/2021_(NCCN®) COVID-19. [accessed by 19 November 2011]. Vaccination Advisory Committee https://www.nccn.org/docs/default-source/covid-19/2021_(NCCN®) COVID-19. [accessed by 19 November 2011]. Vaccination Advisory Committee https://www.nccn.org/docs/default-source/covid-19/2021_(NCCN®) COVID-19. [accessed by 19 November 2011]. Vaccination Advisory Committee https://www.nccn.org/docs/default-source/covid-19/2021_(NCCN®) COVID-19. [accessed by 19 November 2011]. Vaccination Advisory Committee https://www.nccn.org/docs/default-source/covid-19/2021_(NCCN®) COVID-19. [accessed by 19 November 2011]. Vaccination Advisory Committee https://www.nccn.org/docs/default-source/covid-19/2021_(NCCN®) COVID-19. [accessed by 19 November 2011]. Vaccination Advisory Committee https://www.nccn.org/docs/default-source/covid-19/2021_(NCCN®) COVID-19. [accessed by 19 November 2011]. Vaccination Advisory Committee https://www.nccn.org/docs/default-source/covid-19/2021_(NCCN®) COVID-19. [accessed by 19 November 2011]. Vaccination Advisory Committee https://www.nccn.org/docs/default-source/covid-19/2021_(NCCN®) COVID-19. [accessed by 19 November 2011]. Vaccination Advisory Committee https://www.nccn.org/docs/default-source/covid-19/2021_(NCCN®) COVID-19. [accessed by 19 November 2011]. Vaccination Advisory Committee https://www.nccn.org/docs/default-source/covid-19/2021_(NCCN®) COVID-19. [accessed by 19 November 2011]. Vaccination Advisory Committee https://www.nccn.org/docs/default-source/covid-19/2021_(NCCN®) COVID-19. [accessed by 19 November 2011]. Vaccination Advisory Committee https://www.nccn.org/docs/default-source/covid-19/2021_(NCCN®) COVID-19. [accessed by 19 November 2011]. Vaccination Advisory Committee https://www.nccn.org/docs/default-source/covid-19/2021_(NCCN®) COVID-19. [accessed by 19 November 2011]. Vaccination Advisory Committee https://www.nccn.org/docs/default-source/covid-19/2021_(NCCN®) COVID-19. [accessed by 19 November 2011]. Vaccination Advisory Committee https://www.nccn.org/docs/default-source/covid-19/2021_(NCCN®) COVID-19. [accessed by 19 November 2011]. Vaccination Advisory Committee